In order to improve the specific targeting to tumoral cells, a recently-open phase I clinical trial sponsored by the University of Sidney, propose the use of miR-15/16 mimics packaged in EDVTM nanocells targeted with Epidermal Growth Factor Receptor antibodies (TargomiRs) for the treatment of patients with recurrent malignant pleural mesothelioma and non-small cell lung cancer [72]. Here, EGFR is linked to malignant pleural mesothelioma.